Elise's FotoPage

By: Elise MIdy

[Recommend this Fotopage] | [Share this Fotopage]
View complete fotopage

Friday, 21-Jun-2013 06:35 Email | Share | Bookmark
The majority of Promising Newbie: Fun Manufacturing plant P Dist

 
 
 
 
 
 
If you're like me and tend to focus all your What's New attention on the more glitzy New Vibrators Section, you might have missed this little guy's entry. Fun Factory is one of the companies producing incredibly high quality sex toys (you have got to love those Germans - I know I do), so you know even be.t miss doses were up to 73 percent less likely to become infected.

Adherence is a challenge across the board, however. About 50 percent of iPrEx participants were estimated to be adherent to the study protocol.Other studies enrolling both women and men have also produced encouraging effectiveness data.

In Partners PrEP, a study enrolling couples in which one partners was HIV-positive and the other was HIV-negative, effectiveness was shown to be 75 percent and adherence was estimated at 80 percent. The Centers for Disease Control and Preventions (CDC) TDF trial also showed adherence of about 80 percent, and the HIV risk of participants using the product was lowered by 63 percent.So why is it that the two studies conducted exclusively among women did not yield evidence of effectiveness, when other studies enrolling both women and men did?

What are the barriers to adherence that result in women finding themselves unwilling or unable to use this intervention daily? No answers to these questions are immediately apparent, although both the VOICE and the FEM-PrEP data are being further analyzed to look for clues.If PrEP works for women (and men) when they use it, then why don’t women use it? Finding these answers will likely require additional research into the structural and cultural factors that shape behavior, perceptions of risk, and decision-making about sexual and health issues.

The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, released a position statement this week highlighting factors likely to shape PrEP use (or lack of use) among women domestically. Working group Chair Dazon Dixon Diallo, the founder and president of SisterLove, Inc., observed that “[w]hile the clinical science is clear, the social and behavioral implications are less so, and we now need to develop and fund demonstration projects that will help answer a range of questions about real-world use of PrEP by American women and move toward an integrated plan for PrEP rollout in our communities that includes support for healthcare providers, social workers and others who will help women use PrEP effectively.”

Manju Chatani-Gada, senior program manager at AVAC and co-convener of the working group, added that “we have much work to do to understand what social, cultural and other factors affect adherence to the prescribed dose and how we can support women in effectively using new prevention tools. But PrEP remains a valuable option for many women sexuality who will want to and can use it as prescribed. Well-designed demonstration projects will help us understand adherence and other real-world issues for women who choose to use PrEP.”The working group is calling for a coordinated, timely, and adequately funded domestic response to PrEP for women—a response that involves the full participation and leadership of individuals and communities most in need of effective, comprehensive HIV prevention. Its statement calls on the White Houses Office of National AIDS Policy and the CDC to work with the group to develop a national coordination plan for how Truvada will be rolled out to U.S. women.

Given that no clinical trials on PrEP have enrolled American women, the Working Group points out that there is a complete lack of evidence regarding how daily PrEP can best be promoted, made accessible, and financed in ways that ensure its uptake among U.S. women who want to use it and can benefit from it. Prompt actio.ccept to definitely would not accept. The researchers then converted their responses to a 100-point scale.The conjoint analysis revealed that a low out-of-pocket cost was the most important factor to the participants.While we expected cost to be an important factor, we were surprised that it was more important than the ability of the FunZone Vulcan product to actually prevent HIV infection, Galea said.In the conjoint analysis exercise, the preferred scenario was a pill that cost $10 per month; had 95 percent efficacy; had no side effects; would be administered for 10 years; could be taken just before having sex; and would be dispensed by a doctor or nurse at an HIV clinic.

The focus groups' data supported the importance of low cost but also revealed concerns over sexual risk disinhibition, the potential stigma associated with PrEP use and mistrust of health care professionals.Study limitations include the possibility that some subjects may have participated more than others and their views may have been overrepresented as a result; the sample size and researchers' choice of participants buy sex toysmay not make these findings applicable to other groups; and the scenarios chosen may not reflect all possible characteristics.

This research, Galea said, should be extended to other at-risk populations in different settings.We cannot generalize our findings to all persons at risk for HIV, in Peru or elsewhere, he said. But we do propose it as a model for future exploration of the topic, now that oral PrEP has been shown to work but has not yet been scaled up for widespread use.

The National Center on Minority Health and Health Disparities, the National Institute on Aging, the UCLA/Drew Project Export and the UCLA/Drew Center for Health Improvement of Minority Elderly/Resource Center for Minority Aging Research funded this study.Study co-authors are Janni J. Kinsler, Sung-Jae Lee, Jennifer N. Sayles and William E. suction cup dildosCunningham, all of UCLA, and Carlos Cáceres, Ximena Salazar and Maziel Giron of Cayetano Heredia University in Lima, Peru.


View complete fotopage


© Pidgin Technologies Ltd. 2016

ns4008464.ip-198-27-69.net